The immune system is programmed to avoid attacking the body’s own cells and tissues in a mechanism known as self-tolerance. The negative regulators of the immune system, known as immune checkpoints, play a critical role in the maintenance of self-tolerance. In autoimmune diseases self-tolerance is compromised and the immune system mistakenly attacks the body’s own tissues.
Activation of immune checkpoints to control the immune system and re-establish immune tolerance is a new paradigm in the development of therapies for autoimmune diseases. Compugen’s novel immune checkpoints have shown therapeutic efficacy in models of autoimmune diseases, and CGEN-15001 is our lead product candidate in this field.